Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

Overview of attention for article published in BMC Musculoskeletal Disorders, July 2011

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

patent: 3 patents

Citations

dimensions_citation: 130 Dimensions

Readers on

mendeley: 129 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

ANTIBODIES AGAINST IL-1 BETA

Application EP-4001307-A1

European Patent Office

ANTIBODIES AGAINST IL-1 BETA

Grant EP-2931750-B1

European Patent Office

ANTIBODIES AGAINST IL-1 BETA

Application EP-2931750-A1

European Patent Office

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.